RxDoctor Payments Data

Jamie Klumpp, APRN

Primary Care · Sulphur, LANPI 1386066595

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $681 and has fallen 98.0% since, to $14 in 2024.

$857in general payments, 2019–2025

Across 56 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$161
  • Lilly USA, LLC$148
  • AstraZeneca$117
  • Esperion Therapeutics, Inc.$79
  • Novo Nordisk$77
  • Merck$73
  • plus $203 from 6 others

What the payments were for

  • Food & beverage$857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$857 in reported general payments places this provider in the 55th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,655
Medicare patients
67
Services billed
1,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$28,906
RybelsusSemaglutide12$11,435
EliquisApixaban11$6,364
Duloxetine Hcl16$1,241
Levothyroxine Sodium81$1,176
Pantoprazole Sodium61$1,158
SynthroidLevothyroxine Sodium15$1,024
Atorvastatin Calcium64$990
Montelukast Sodium59$821
Labetalol Hcl13$650
Losartan Potassium37$526
Doxycycline Monohydrate17$485
Pregabalin21$483
Alprazolam29$478
Celecoxib14$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$148$28,90624 claims
Novo NordiskRybelsus$77$11,43512 claims
AbbVieSynthroid$161$1,02415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 106 primary care providers in Louisiana.

Other primary care in Sulphur

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →